Cabaletta Bio
Update in progressCABA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. Its lead product, resecabtagene autoleucel (CD19-CAR T with a 4-1BB co-stimulatory domain), is in Phase 1/2 for diseases including dermatomyositis, lupus, and multiple sclerosis. DSG3-CAART and MuSK-CAART are in Phase 1 for mucosal pemphigus vulgaris and MuSK-positive myasthenia gravis. Collaborations include UPenn/CHOP, Nanjing IASO, Oxford Biomedica, Autolus, WuXi. Based in Philadelphia; formerly Tycho Therapeutics.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Steven A. Nichtberger M.D.
- Founded2017
- Employees154
- Websitewww.cabalettabio.com
Identifiers
- ISINUS12674W1099
- FIGIBBG00MJ3BKW2
- CUSIP12674W109
- CIK0001759138